Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
WASHINGTON, April 11, 2016 -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use of safe and effective regenerative cell therapies in the United States. The April 12th event, Advancing a New Policy Framework for Regenerative Cell Therapy—which begins at 9:30am EST and will be webcast live—will bring together scientific and academic experts, patients, practitioners, and industry to discuss the science behind cell therapy and new policies needed to modernize the current U.S. regulatory approach.
In addition to co-hosting the event, the Regenerative Medicine Foundation is collaborating with BPC to convene and engage a broad societal-based alliance of non-profit patient groups, medical philanthropies, academic centers, industry organizations, and other advocates to support a new regulatory pathway for safe and effective cell therapies in the U.S.
"With the recent introduction of the bipartisan, bicameral REGROW Act, the time has arrived for us to move from laboratories into the clinic," said Bernie Siegel, executive director of the Regenerative Medicine Foundation and founder and chair of the annual World Stem Cell Summit & RegMed Capital Conference. "Cell therapies are different from drugs, and they have the vast potential to alleviate human suffering. We need to support the FDA in accelerating safe and effective cell therapy treatments, and the Regenerative Medicine Foundation is committed to this humanitarian cause."
"We are delighted to be working with the Regenerative Medicine Foundation to advance regenerative cell therapy—which represents one of the most promising areas for the next generation of groundbreaking treatments," said Janet Marchibroda, director of BPC's health innovation initiative. "Through our work together, we are advancing public policy that will accelerate the availability of safe and effective treatments for Americans and improve U.S. competitiveness in the global marketplace."
About the Regenerative Medicine Foundation
The nonprofit Regenerative Medicine Foundation, formerly known as the Genetics Policy Institute, is an influential global network of stakeholders from patient-advocacy, science, and industry that serves as a catalyst and provides leadership to the pro-cures movement. Through RMF's action network, reports, newsletters, the flagship World Stem Cell Summit and RegMed Capital Conference, special projects, speaking engagements, world-renowned advisory boards, educational resources, teaching initiatives, and strategic relationships, RMF serves as the foremost channel of knowledge between leading regenerative medicine experts, patient advocates, and those who make policy for the general public.
CONTACT: Alan Fernandez
650-759-8300
[email protected]
